Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant KRAS Downregulates the Receptor for Leukemia Inhibitory Factor (LIF) to Enhance a Signature of Glycolysis in Pancreatic Cancer and Lung Cancer.

Molecular cancer research : MCR - 1 Aug 2021

Liu Suhu, Gandler Helen I, Tošić Isidora, Ye Darwin Q, Giaccone Zachary T, Frank David A

Abstract excerpt

Pancreatic cancer is characterized by aberrant activity of oncogenic KRAS, which is mutated in 90% of pancreatic adenocarcinomas. Because KRAS itself is a challenging therapeutic target, we focused on understanding key signaling pathways driven by KRAS as a way to reveal dependencies that are amenable to therapeutic intervention. Analyses in primary human pancreatic cancers and model systems revealed that the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Down-Regulation
Share to Glycolysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia Inhibitory Factor

Share to Lung Neoplasms

Share to NIH 3T3 Cells

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to STAT3 Transcription Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 33931487
DOI: 10.1158/1541-7786.MCR-20-0633
PMCID: PMC8349878

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant KRAS Downregulates the Receptor for Leukemia Inhibitory Factor (LIF) to Enhance a Signature of Glycolysis in Pancreatic Cancer and Lung Cancer.PMID 33931487Read ↗

Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor MicroenvironmentSemantic proximity Read ↗

Simultaneous inhibition of PFKFB3 and GLS1 selectively kills KRAS-transformed pancreatic cells.Semantic proximity Read ↗

p38γ MAPK Is Essential for Aerobic Glycolysis and Pancreatic TumorigenesisSemantic proximity Read ↗

KRAS: feeding pancreatic cancer proliferation.Semantic proximity Read ↗

Oncogenic KRASG12D Reprograms Lipid Metabolism by Upregulating SLC25A1 to Drive Pancreatic TumorigenesisSemantic proximity Read ↗

STAT3 is a genetic modifier of TGF-beta induced EMT in KRAS mutant pancreatic cancerSemantic proximity Read ↗

Targeting metabolic reprogramming in KRAS-driven cancers.Semantic proximity Read ↗

STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis.Semantic proximity Read ↗

STAT3 sustains tumorigenicity following mutant KRAS ablation.Semantic proximity Read ↗

Loss of STK11 Suppresses Lipid Metabolism and Attenuates KRAS-Induced Immunogenicity in Patients with Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Netrin G1 Promotes Pancreatic Tumorigenesis through Cancer-Associated Fibroblast–Driven Nutritional Support and ImmunosuppressionSemantic proximity Read ↗

STAT3 is a genetic modifier of TGF-beta induced EMT in KRAS mutant pancreatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.